Whole blood clots are more resistant to lysis than plasma clots - Greater efficacy of rivaroxaban

Thrombosis Research

Volumn 131, Issue 3, 2013, Pages

  Varin, Rémi ^a,b,c   Mirshahi, Shahsultan ^d   Mirshahi, Pezhman ^a,c   Klein, Christophe ^a   Jamshedov, Jovid ^c   Chidiac, Jean ^c   Perzborn, Elisabeth ^e   Mirshahi, Massoud ^a,c   Soria, Claudine ^b   Soria, Jeannette ^a,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c HÔTEL DIEU   (France)

^d Research and Development   (France)

^e BAYER PHARMA AG   (Germany)

Author keywords

anticoagulants; clot permeability; clot structure; red blood cells; rivaroxaban; whole blood clot degradability

Indexed keywords

D DIMER; PLASMINOGEN; RIVAROXABAN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOWMETRY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; FIBRIN CLOT; PERMEABILITY; PRIORITY JOURNAL; THROMBIN TIME;

ANTICOAGULANTS; BLOOD; BLOOD COAGULATION; BLOOD PLATELETS; ERYTHROCYTES; FACTOR XIII; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; MORPHOLINES; PERMEABILITY; PLASMA; RISK FACTORS; THIOPHENES; THROMBIN; THROMBOLYTIC THERAPY; THROMBOPLASTIN; THROMBOSIS; TIME FACTORS;

EID: 84875254531     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.11.029     Document Type: Article

References (63)

1. T. Lisman, P.G. de Groot, J.C. Meijers, and F.R. Rosendaal Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis Blood 105 2005 1102 1105
2. M.E. Meltzer, C.J. Doggen, P.G. de Groot, F.R. Rosendaal, and T. Lisman The impact of the fibrinolytic system on the risk of venous and arterial thrombosis Semin Thromb Hemost 35 2009 468 477
3. J. Soria, C. Soria, and J.P. Caen A new type of congenital dysfibrinogenaemia with defective fibrin lysis - Dusard syndrome: Possible relation to thrombosis Br J Haematol 53 1983 575 586
4. J.P. Collet, J. Soria, M. Mirshahi, M. Hirsch, F.B. Dagonnet, and J. Caen Dusart syndrome: A new concept of the relationship between fibrin clot architecture and fibrin clot degradability: Hypofibrinolysis related to an abnormal clot structure Blood 82 1993 2462 2469
5. D.A. Gabriel, K. Muga, and E.M. Boothroyd The effect of fibrin structure on fibrinolysis J Biol Chem 267 1992 24259 24263
6. M.E. Meltzer, T. Lisman, C.J. Doggen, P.G. de Groot, and F.R. Rosendaal Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis PLoS Med 5 2008 751 758
7. A. Undas, K. Szułdrzynski, E. Stepien, J. Zalewski, J. Godlewski, and W. Tracz Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: Effects of inflammation and oxidative stress Atherosclerosis 196 2008 551 557
8. A. Undas, P. Podolec, K. Zawilska, M. Pieculewicz, I. Jedliński, and E. Stȩpień Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke Stroke 40 2009 1499 1501
9. J.P. Collet, Y. Allali, C. Lesty, M.L. Tanguy, J. Silvain, and A. Ankri Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis Arterioscler Thromb Vasc Biol 26 2006 2567 2573
10. K. Fatah, A. Hamsten, B. Blombäck, and M. Blombäck Fibrin gel network characteristics and coronary heart disease: Relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis Thromb Haemost 68 1992 130 135
11. K. Fatah, A. Silveira, P. Tornvall, F. Karpe, M. Blombäck, and A. Hamsten Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age Thromb Haemost 76 1996 535 540
12. B. Blombäck, D. Banerjee, K. Carlsson, A. Harnsten, B. Hessel, and R. Procyk Native fibrin gel networks and factors influencing their formation in health and disease Adv Exp Med Biol 281 1990 1 23
13. B. Blombäck, K. Carlsson, K. Fatah, B. Hessel, and R. Procyk Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation Thromb Res 75 1994 521 538
14. A.S. Wolberg, D.M. Monroe, H.R. Roberts, and M. Hoffman Elevated prothrombin results in clots with an altered fiber structure: A possible mechanism of the increased thrombotic risk Blood 101 2003 3008 3013
15. A.S. Wolberg Thrombin generation and fibrin clot structure Blood Rev 21 2007 131 142
16. Y. Cadroy, and S.R. Hanson Effects of red blood cell concentration on hemostasis and thrombus formation in a primate model Blood 75 1990 2185 2193
17. Y. Qi, B. Gazelius, B. Linderoth, and T. Lundeberg Arterial blood flow and microcirculatory changes in a rat groin flap after thrombosis induced by electrical stimulation of the artery Microvasc Res 63 2002 179 185
18. K.D. Kurz, B.W. Main, and G.E. Sandusky Rat model of arterial thrombosis induced by ferric chloride Thromb Res 60 1990 269 280
19. C. Longstaff, C. Thelwell, S.C. Williams, M.M. Silva, L. Szabó, and K. Kolev The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: Kinetic and microscopic studies Blood 117 2011 661 668
20. S.K. Braekkan, E.B. Mathiesen, I. Njølstad, T. Wilsgaard, and J.B. Hansen Hematocrit and risk of venous thromboembolism in a general population. The Tromsø study Haematologica 95 2010 270 275
21. D.A. Andrews, and P.S. Low Role of red blood cells in thrombosis Curr Opin Hematol 6 1999 76 82
22. D. Grisaru, E. Zwang, M.R. Peyser, J.B. Lessing, and A. Eldor The procoagulant activity of red blood cells from patients with severe preeclampsia Am J Obstet Gynecol 177 1997 1513 1516
23. E. Perzborn Factor Xa inhibitors - new anticoagulants for secondary haemostasis Hamostaseologie 29 2009 260 267
24. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59Â7939 - an oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521
25. J. Harenberg, and M. Wehling Current and future prospects for anticoagulant therapy: Inhibitors of factor Xa and factor IIa Semin Thromb Hemost 34 2008 39 57
26. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, W. Mueck, and V. Laux Rivaroxaban: A new oral factor Xa inhibitor Arterioscler Thromb Vasc Biol 30 2010 376 381
27. S. Haas Rivaroxaban - an oral, direct Factor Xa inhibitor: Lessons from a broad clinical study programme Eur J Haematol 82 2009 339 349
28. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
29. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial Lancet 372 2008 31 39
30. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
31. A.G.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial Lancet 373 2009 1673 1680
32. M.E. Nesheim, J.B. Taswell, and K.G. Mann The contribution of bovine Factor V and Factor Va to the activity of prothrombinase J Biol Chem 254 1979 10952 10962
33. K.G. Mann, K. Brummel, and S. Butenas What is all that thrombin for? J Thromb Haemost 1 2003 1504 1514
34. J. Ansell Factor Xa or thrombin: Is factor Xa a better target? J Thromb Haemost 5 Suppl. 1 2007 60 64
35. G.T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M.M. Samama In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban J Thromb Haemost 5 2007 886 888
36. G. Leone, S. Sica, P. Chiusolo, L. Teofili, and V. De Stefano Blood cells diseases and thrombosis Haematologica 86 2001 1236 1244
37. D.M. Monroe, and M. Hoffman What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26 2006 41 48
38. R. Kumar, S. Béguin, and H.C. Hemker The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity Thromb Haemost 74 1995 962 968
39. C. Weinz, U. Buetehorn, H.P. Daehler, C. Kohlsdorfer, U. Pleiss, and S. Sandmann Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs Xenobiotica 35 2005 891 910
40. M. Okada, and B. Blombäck Factors influencing fibrin gel structure studied by flow measurement Ann N Y Acad Sci 408 1983 233 253
41. S. He, H. Cao, A. Antovic, and M. Blombäck Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials Blood Coagul Fibrinolysis 16 2005 61 67
42. S. Mirshahi, C. Soria, J. Chidiac, G. Kierzek, R. Varin, and R. Batista Determination of activated factor XIII in plasma as a marker of activation of coagulation [abstract] 2009 International Society on Thrombosis and Haemostasis [XXth Congress:abstract PP-TH-211]
43. J.S. Collins, and T.H. Goldsmith Spectral properties of fluorescence induced by glutaraldehyde fixation J Histochem Cytochem 29 1981 411 414
44. J.P. Collet, D. Park, C. Lesty, J. Soria, C. Soria, and G. Montalescot Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: Dynamic and structural approaches by confocal microscopy Arterioscler Thromb Vasc Biol 20 2000 1354 1361
45. A. Undas, M. Celinska-Löwenhoff, T. Löwenhoff, and A. Szczeklik Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease J Thromb Haemost 4 2006 1029 1036
46. K. Suzuki, Y. Muto, K. Fushihara, K. Kanemoto, H. Iida, and E. Sato Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3- phenylpropanoylamino) propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B J Pharmacol Exp Ther 309 2004 607 615
47. V. Peyrou, J.C. Lormeau, J.P. Hérault, C. Gaich, A.M. Pfliegger, and J.M. Herbert Contribution of erythrocytes to thrombin generation in whole blood Thromb Haemost 81 1999 400 406
48. K.C. Lounes, C. Soria, S.S. Mirshahi, P. Desvignes, M. Mirshahi, and O. Bertrand Fibrinogen Alès: A homozygous case of dysfibrinogenemia (gamma-Asp(330) - >Val) characterized by a defective fibrin polymerization site «a» Blood 96 2000 3473 3479
49. J.M. van Gelder, C.H. Nair, and D.P. Dhall Erythrocyte aggregation and erythrocyte deformability modify the permeability of erythrocyte enriched fibrin network Thromb Res 82 1996 33 42
50. K.C. Gersh, C. Nagaswami, and J.W. Weisel Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes Thromb Haemost 102 2009 1169 1175
51. J.W. Weisel, and R.I. Litvinov The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate Cardiovasc Hematol Agents Med Chem 6 2008 161 180
52. N. Wohner, P. Sótonyi, R. Machovich, L. Szabó, K. Tenekedjiev, and M.M. Silva Lytic resistance of fibrin containing red blood cells Arterioscler Thromb Vasc Biol 31 2011 2306 2313
53. F.A. Carvalho, S. Connell, G. Miltenberger-Miltenyi, S. Vale Pereira, A. Tavares, and R. Ariëns Atomic Force Microscopy-Based Molecular Recognition of a Fibrinogen Receptor on Human Erythrocytes ACS Nano 4 2010 4609 4620
54. W. Mueck, B.I. Eriksson, K.A. Bauer, L. Borris, O.E. Dahl, and W.D. Fisher Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery Clin Pharmacokinet 47 2008 203 216
55. R. Varin, S. Mirshahi, P. Mirshahi, G. Kierzek, D. Sebaoun, and Z. Mishal Clot structure modification by fondaparinux and consequence on fibrinolysis: A new mechanism of antithrombotic activity Thromb Haemost 97 2007 27 31
56. S. He, M. Blombäck, N. Bark, H. Johnsson, and N.H. Wallén The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis Thromb Haemost 103 2010 1076 1084
57. R.A. Ariëns, H. Philippou, C. Nagaswami, J.W. Weisel, D.A. Lane, and P.J. Grant The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure Blood 96 2000 988 995
58. M. Nesheim, W. Wang, M. Boffa, M. Nagashima, J. Morser, and L. Bajzar Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis Thromb Haemost 78 1997 386 391
59. L. Bajzar, M.E. Nesheim, and P.B. Tracy The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent Blood 88 1996 2093 2100
60. N.J. de Fouw, F. Haverkate, and R.M. Bertina Protein C and fibrinolysis: A link between coagulation and fibrinolysis Adv Exp Med Biol 281 1990 235 243
61. M.K. Horne, A.M. Cullinane, P.K. Merryman, and E.K. Hoddeson The effect of red blood cells on thrombin generation Br J Haematol 133 2006 403 408
62. Y.N. Zheng, H.J. Yu, J.X. Hou, C.F. Lu, and J. Zhou Lactadherin and procoagulant activities of red blood cells in cyclosporine induced thrombosis Chin Med J 122 2009 1674 1680
63. M. Blombäck, S. He, N. Bark, H.N. Wallen, and M. Elg Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate Br J Haematol 152 2011 758 765